Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01182857|
Recruitment Status : Withdrawn
First Posted : August 17, 2010
Last Update Posted : September 20, 2018
- Severe combined immunodeficiency (SCID) is a rare inherited disorder in which certain white blood cells have impaired function and are unable to properly fight infections. SCID typically appears within the first year of life and is characterized by multiple, recurrent severe infections. More than 10 percent of all cases of SCID involve a deficiency of an enzyme called adenosine deaminase (ADA), and these SCID patients also tend to have impaired brain function or psychiatric disorders. Researchers are attempting to treat ADA-SCID patients with an experimental gene therapy, and a research protocol has been established for those who are participating in this therapy.
- Little is known about quality of life in individuals with ADA-SCID, but researchers believe that the effects of the disease and the treatments may cause a decreased quality of life in both patients and their parents. Another potential cause of decreased quality of life in ADA-SCID is the associated psychiatric and neurological problems caused by the disease. Researchers are interested in studying quality of life in individuals with ADA-SCID and their parents to provide more information about the disease.
- To evaluate whether gene therapy alters the quality of life or neuropsychiatric status of children with ADA-SCID.
- To monitor for intellectual, attention, memory, or specific learning disorders in children with ADA-SCID.
- To evaluate whether undergoing gene therapy has an effect on parenting stress of parents whose children have ADA-SCID.
- Children who are participating in the ADA-SCID gene therapy research protocol (01-HG-0189).
- Parents of children who are participating in the ADA-SCID gene therapy research protocol (01-HG-0189).
- All of the testing and questionnaires will be done in the pediatric or adult clinic.
- Participating children will have tests of intelligence, manual dexterity, reaction time, basic reading and arithmetic skills, speech, and memory. These tests will be given before the start of the therapy, and then once a year for 5 years.
- Participating children will also complete questionnaires on quality of life. These questionnaires will be given before the start of the therapy, 3 months and 6 months after the therapy, and then every 6 months for a total of 5 years.
- Additional psychological tests may be given at the discretion of the study researchers.
- Parents will complete questionnaires to provide background medical information and report on quality of life and parental stress. The background information questionnaires will be given at the start of the therapy and then once a year for 5 years, the parental stress questionnaires will be given at the start of the therapy and then every 6 months for 5 years, and the quality of life questionnaires will be given at the same time as the child quality of life questionnaires.
- This protocol is separate from the gene therapy treatment protocol....
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents|
|Study Start Date :||August 5, 2010|
|Study Completion Date :||September 25, 2014|
- Quality of life and neuropsychiatric status of patients being treated with gene therapy for ADA-SCID. [ Time Frame: 2 years ]
- Parental stress in parents of children being treated with gene therapy for ADA-SCID. [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01182857
|Principal Investigator:||Robert A Sokolic, M.D.||National Human Genome Research Institute (NHGRI)|